Dipyridamole (Persantin-Boehringer Ingelheim) was introduced in 1959 as a vasodilator for the treatment of angina, but it is now little used for this purpose. The discovery of its effects on platelets has led to its widespread use in a variety of thrombotic conditions, both alone and in combination with other drugs. The manufacturer claims that dipyridamole “offers a real opportunity in the prevention of thromboembolic disease” and the NHS spends well over £5 million a year on the drug. What is the evidence for its clinical efficacy?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.